Vir and Gilead Partner on 1.9B Cancer Deal
Vir Biotechnology and Gilead Sciences formed a collaboration worth up to 1.9 billion dollars to develop solid tumor cancer treatments. Vir will use its proprietary technology to design three novel drug candidates while Gilead handles clinical testing.
Xurve View
Insights:
Xurve View
Vir Biotechnology signed a partnership worth up to $1.88B with Gilead Sciences on Wednesday morning to develop solid tumor cancer therapies. The deal sent Vir's shares up 12% in premarket trading. The collaboration targets three dual-masked T-cell engager candidates designed to direct immune responses against solid tumors.
